@article{5fed341d35ce4185837fc74faf1b35a6,
title = "Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma",
abstract = "Background. Serum Golgi membrane protein 1 (GOLM1) is a novel biomarker for hepatocellular carcinoma (HCC). However, few studies have investigated the relationship between GOLM1 protein expression and clinicopathologic features in HCC patients. The aim of this study was to investigate the expression of GOLM1 in human HCC and its correlation with clinicopathologic parameters. Methods. Clinicopathologic data were obtained through a detailed retrospective review of the medical records of 193 patients with HCC who had undergone surgical resection between 1990 and 2006 at the Taipei Veterans General Hospital. Another 120 HCC tissue samples provided by the Taiwan Liver Cancer Network were used as validation cohort. Immunohistochemical staining was used to determine the expression of GOLM1 in archived formalin-fixed, paraffin-embedded tissue specimens. Results. GOLM1 expression was significantly higher in resected HCC tumor tissues than in corresponding normal liver tissues (p\0.01). After a median follow-up of 51 months, multivariate analysis showed that portal vein invasion (hazard ratio [HR], 1.515; 95 % confidence interval [95 % CI], 1.008-2.277; p = 0.046) and high GOLM1 protein expression (HR, 1.696; 95 % CI, 1.160-2.479; p = 0.006) were independent prognostic factors for poor overall survival. High GOLM1 protein expression still significantly correlates with worse overall survival as well as disease-free survival in the validation cohort (p\0.001 and p = 0.002). Conclusions. Overexpression of GOLM1 is associated with poor prognosis in human HCC.",
author = "Chen, {Ming Huang} and Jan, {Yi Hua} and Chang, {Peter Mu Hsin} and Chuang, {Yung Jen} and Yeh, {Yi Chen} and Lei, {Hao Jan} and Michael Hsiao and Huang, {Shiu Feng} and Huang, {Chi Ying F.} and Chau, {Gar Yang}",
note = "Funding Information: The HCC tissue samples of validation cohort were provided by the Taiwan Liver Cancer Network (TLCN). The TLCN is funded by the National Science Council to provide primary liver cancer tissue and associated clinical information. The use of the 120 HCC tissues in this study was approved by our Institutional Review Board and the TLCN User Committee. Funding Information: ACKNOWLEDGMENT This research was supported by grants from Taipei Veterans General Hospital (V102E2-007), Yen Tjing Ling Medical Foundation and Taiwan Clinical Oncology Research Foundation to M.-H. Chen and National Science Council (NSC100-2627-B-010-005), National Health Research Institutes (NHRI-EX101-10029BI), Taipei Veterans General Hospital (V102E2-006 and VGHUST101-G5-1-2), and Ministry of Education Aim for the Top University Plan (National Yang Ming University) to C. Y. Huang. We would like to thank Taiwan Liver Cancer Network (TLCN) for providing the HCC tissue samples and related clinical data (all are anonymous) for our research work. This network currently includes five major medical centers (National Taiwan University Hospital, Chang-Gung Memorial Hospital-Linko, Veteran General Hospital-Taichung, Chang-Gung Memorial Hospital -Kaohsiung, and Veteran General Hospital -Kaohsiung). TLCN is supported by grants from National Science Council since 2005 till now (NSC 100-2325 -B-182 -006) and National Health Research Institutes, Taiwan.",
year = "2013",
doi = "10.1245/s10434-013-3101-8",
language = "English",
volume = "20",
pages = "S616--S624",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3 SUPPL.",
}
